August 14, 2023. Finerenone Reduces Albuminuria in a Dose-dependant Way in Patients with Diabetic Nephropathy

Does the therapy with finerenone reduce the albuminuria in patients with diabetic nephropathy? Is the effect dose-dependant? The following article explored the questions.

Article name: Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. A Randomized Clinical Trial

Link
DOI

This article was published in JAMA in 2015. It is a randomized controlled trial (RCT):
The mean placebo-corrected ratios of UACR at day 90 vs baseline in the finerenone groups:

Finerenone Dose	Mean placebo-corrected ratios of UACR at day 90 vs baseline	p
7.5 mg	0.79	0.004
10 mg	0.76	0.001
15 mg	0.67	< 0.001
20 mg	0.62	< 0.001

Finerenone is a nonsteroidal, highly selective mineralocorticoid receptor antagonist (MRA) with a greater affinity for the mineralocorticoid receptor than eplerenone. The study was a RCT, double-blind, and placebo-controlled. Most of the patients of the study were already receiving RAS blockade. Finerenone reduced the placebo-corrected urine albumin/creatinine ratio (UACR) at day 90 in a dose-dependent manner, with a significant reduction in UACR ranging from 21% to 38% in the finerenone dosage groups of 7.5 to 20 mg/d compared with placebo

Any information or statement present in this post does not replace your health care provider’s advice or treatment. This blog does not provide medical advice, prescribe medications or therapies, or diagnose conditions, it only expresses an opinion. If you have a health-related question or condition, confer with your healthcare provider.